4.5 Article

Confocal Endomicroscopy Identifies Loss of Local Barrier Function in the Duodenum of Patients with Crohn's Disease and Ulcerative Colitis

期刊

INFLAMMATORY BOWEL DISEASES
卷 20, 期 5, 页码 892-900

出版社

OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000027

关键词

confocal endoscopy; ulcerative colitis; Crohn's disease; barrier function; epithelial integrity

资金

  1. Wellcome Trust [WT0087768MA]
  2. Pentax Europe
  3. BBSRC [BBS/E/F/00044446] Funding Source: UKRI
  4. Biotechnology and Biological Sciences Research Council [BBS/E/F/00044446] Funding Source: researchfish

向作者/读者索取更多资源

Background: Increased cell shedding with gap formation and local barrier dysfunction can be identified endomicroscopically in the terminal ileum of patients with inflammatory bowel disease. We aim to evaluate whether these changes are also present in the duodenum of patients with inflammatory bowel disease. Methods: Fifteen patients with Crohn's disease (CD), 10 patients with ulcerative colitis (UC), and 10 controls underwent fluorescein-aided confocal laser endomicroscopy (CLE). CLE was performed on macroscopically normal antral and duodenal (D1, D2, D3, D4) mucosa. Representative CLE images were prospectively analyzed. Images were scored for the number of epithelial gaps, cell shedding, and the degree of fluorescein leakage into the intestinal lumen. Results: Both CD and UC patients had significantly more epithelial gaps, epithelial cell shedding, and leakage of fluorescein into the duodenal lumen than controls. The degree of cell shedding and epithelial gap formation was similar in CD and UC patients. In all cases, macroscopic endoscopic appearances of the duodenum were normal, and conventional histological analysis showed a mild nonspecific duodenitis in 7 of 15 patients with CD. Patients with UC had a histologically normal duodenum. Gap formation, cell shedding, and fluorescein leakage was similar in CD with active compared with inactive disease, except for D2 shedding. Conclusions: CLE can detect epithelial damage and barrier loss in the duodenum of CD and UC patients that is not apparent on conventional endoscopy or histology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report

Marie-Kristin Schwaegermann, Lukas Hobohm, Johanna Rausch, Michael Reuter, Thomas-Friedrich Griemert, Visvakanth Sivanathan, Tanja Falter, Martin F. Sprinzl, Karl J. Lackner, Peter R. Galle, Stavros Konstantinides, Matthias Theobald, Charis von Auer

Summary: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare autoimmune disorder characterized by reduced activity of ADAMTS13 due to autoantibodies. This results in thrombotic microangiopathy, decreased platelet count, hemolysis, and tissue ischemia.

HAMOSTASEOLOGIE (2023)

Article Oncology

Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance

Benjamin Ruf, Cristiana Roggia, Christopher Schroeder, Sven Mattern, Falko Fend, Thomas Klag, Martin Goetz

Summary: Chromoendoscopy can facilitate the detection of gastric carcinoma foci in CDH1 mutation carriers. While chromoendoscopy identified all patients with gastric cancer, not all cancer foci present in these patients were detected. Therefore, the addition of chromoendoscopy to white light endoscopy could be used to enhance the diagnostic reliability of endoscopic surveillance for patients opting against prophylactic total gastrectomy.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Letter Gastroenterology & Hepatology

Reply to: SEAL: Why was this approach not effective?

Christian Labenz, Frank Lammert, Peter R. Galle

JOURNAL OF HEPATOLOGY (2023)

Article Health Care Sciences & Services

Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV

Maurice Michel, Alisha Wahl, Malena Anders, Saleh A. Alqahtani, Wolfgang M. Kremer, Peter R. Galle, Christian Labenz, Daniel Grimm, Martin Sprinzl, Joern M. Schattenberg

Summary: Metabolic comorbidities, significant fibrosis, and a lower socioeconomic status may negatively affect the health-related quality of life in people living with human immunodeficiency virus (HIV).

QUALITY OF LIFE RESEARCH (2023)

Article Oncology

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng

Summary: The IMbrave150 trial showed that atezolizumab + bevacizumab is safe and effective in treating patients with hepatocellular carcinoma, including those with hepatitis B or hepatitis C infection.

LIVER CANCER (2023)

Article Gastroenterology & Hepatology

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome

Sophia Heinrich, Thomas Austgen, Darko Castven, Moritz Hess, Christian Labenz, Martha Kirstein, Carolin Zimpel, Lena Stockhoff, Benjamin Maasoumy, Bernd Heinrich, Hans Heinrich Wedemeyer, Peter Robert Galle, Harald Binder, Marc Nguyen-Tat, Jens Uwe Marquardt

Summary: In this study, serum levels of M30 and M65 were found to be able to effectively distinguish responders from non-responders to terlipressin therapy in patients with hepatorenal syndrome (HRS), and predict dialysis- and liver transplantation (LTX)-free survival.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Article Oncology

IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study

Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni

Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.

LIVER CANCER (2023)

Article Gastroenterology & Hepatology

Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio Del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose G. Ferraz, Martin Goetz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarey, Remo Panaccione, Adolfo Parra-Blanco, Luca Pastorelli, Timo Rath, Elin S. Royset, Gian Eugenio Tontini, Michael Vieth, Davide Zardo, Subrata Ghosh, Valery Naranjo, Vincenzo Villanacci

Summary: An artificial intelligence computer-aided diagnosis system was developed and validated to evaluate UC biopsies and predict prognosis. The system showed high accuracy and sensitivity in assessing biopsy results and predicting outcomes.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

S3 guideline diagnostics and therapy of biliary carcinoma - long version

Michael Bitzer, Sabrina Gross, Joerg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Goetz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kautz, David Krug, Christian La Fougere, Hauke Lang, Philipp Lenz, Tom Luedde, Andreas Mahnken, Silvio Nadalin, Hoa Huu Phuc Nguyen, Johann Ockenga, Karl Oldhafer, Philipp Paprottka, Philippe Pereira, Thorsten Persigehl, Ruben Plentz, Juergen Pohl, Heinrich Recken, Peter Reimer, Jutta Riemer, Ulrike Ritterbusch, Elke Roeb, Joern Ruessel, Barbara Schellhaas, Peter Schirmacher, Hans Juergen Schlitt, Irene Schmid, Andreas Schuler, Daniel Seehofer, Marianne Sinn, Andreas Stengel, Christoph Stoll, Andrea Tannapfel, Anne Taubert, Reina Tholen, Joerg Trojan, Ingo van Thiel, Arndt Vogel, Thomas Vogl, Frank Wacker, Oliver Waidmann, Heiner Wedemeyer, Henning Wege, Dane Wildner, Marcus-Alexander Woerns, Peter Galle, Nisar Malek

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Article Gastroenterology & Hepatology

S3 guideline diagnostics and therapy of biliary carcinoma

Michael Bitzer, Sabrina Gross, Joerg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Goetz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kautz, David Krug, Christian La Fougere, Hauke Lang, Philipp Lenz, Tom Luedde, Andreas Mahnken, Silvio Nadalin, Hoa Huu Phuc Nguyen, Johann Ockenga, Karl Oldhafer, Philipp Paprottka, Philippe Pereira, Thorsten Persigehl, Ruben Plentz, Juergen Pohl, Heinrich Recken, Peter Reimer, Jutta Riemer, Ulrike Ritterbusch, Elke Roeb, Joern Ruessel, Barbara Schellhaas, Peter Schirmacher, Hans Juergen Schlitt, Irene Schmid, Andreas Schuler, Daniel Seehofer, Marianne Sinn, Andreas Stengel, Christoph Stoll, Andrea Tannapfel, Anne Taubert, Reina Tholen, Joerg Trojan, Ingo van Thiel, Arndt Vogel, Thomas Vogl, Frank Wacker, Oliver Waidmann, Heiner Wedemeyer, Henning Wege, Dane Wildner, Marcus-Alexander Woerns, Peter Galle, Nisar Malek

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Article Oncology

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel

Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.

LIVER CANCER (2023)

Review Gastroenterology & Hepatology

Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis

Simon J. Gairing, Eva M. Schleicher, Peter R. Galle, Christian Labenz

Summary: Hepatic encephalopathy is a significant complication of liver cirrhosis with detrimental effects on patients' quality of life. Identifying high-risk patients and implementing early prevention is crucial. Cognitive tests, composite scores, and blood-based biomarkers have shown promise in predicting the first-time occurrence of hepatic encephalopathy. However, the evidence for primary prophylaxis is limited.

HEPATOLOGY COMMUNICATIONS (2023)

Article Cardiac & Cardiovascular Systems

Cumulative social disadvantage and cardiovascular disease burden and mortality

Omar Hahad, Donya A. Gilan, Julian Chalabi, Sadeer Al-Kindi, Alexander K. Schuster, Felix Wicke, Matthias Buettner, Oliver Tuescher, Karl J. Lackner, Peter R. Galle, Stavros Konstantinides, Andreas Daiber, Philipp S. Wild, Thomas Muenzel

Summary: This study aims to investigate the association between social disadvantage and cardiovascular burden and mortality. The findings suggest that low socioeconomic status is associated with increased risk of cardiovascular disease and mortality, with education and occupation being stronger predictors compared to household net income.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Biochemistry & Molecular Biology

Reduced Lipid Peroxidation Predicts Unfavorable Prognosis in Hepatocellular Carcinoma, but Not Intrahepatic Cholangiocarcinoma

Tiemo Sven Gerber, Hagen Roland Witzel, Arndt Weinmann, Fabian Bartsch, Mario Schindeldecker, Peter R. Galle, Hauke Lang, Wilfried Roth, Dirk Andreas Ridder, Beate Katharina Straub

Summary: This study investigated the levels of 4-hydroxy-nonenal (4-HNE) in liver carcinomas and analyzed their correlation with clinical data and survival outcomes. The results showed that lower levels of 4-HNE were associated with unfavorable survival outcomes and aggressive tumor behavior in hepatocellular carcinoma (HCC). However, in intrahepatic cholangiocarcinoma (iCCA), 4-HNE levels were not correlated with prognostic parameters or survival outcomes.

BIOMEDICINES (2023)

Letter Gastroenterology & Hepatology

Ammonia - an old friend with a new area of application

Simon Johannes Gairing, Leonard Kaps, Eva Maria Schleicher, Peter Robert Galle, Christian Labenz

JOURNAL OF HEPATOLOGY (2023)

暂无数据